Aehr Test Systems: A Spot of Luck, Perhaps?

Now, Aehr Test Systems (AEHR 5.34%), a name which, let’s face it, doesn’t exactly trip off the tongue, has been having a positively ripping time of late. While the broader market was looking a bit peakish in February – the S&P 500 dipping its toe into the chilly waters of a 0.9% decline, and the Nasdaq Composite taking a rather more substantial plunge of 3.4% – Aehr’s shares went absolutely stratospheric, rocketing upwards by a most agreeable 46%. One begins to wonder if someone up there is feeling particularly benevolent, or if a spot of good fortune has simply blown its way.

It appears the company has been rather successful in securing some new contracts, a development which, naturally, tickled the fancy of investors. Year to date, the stock has climbed a most impressive 100.5%, a performance that suggests either a genius stroke of management or a temporary lapse in the collective judgment of the financial world. One suspects it’s a bit of both, what?

A Surge of Contracts, By Jove!

The good news, as it were, began on February 11th, when Aehr announced it had landed a rather substantial order for its Sonoma systems – devices used for testing and “burn-in” of those complicated artificial intelligence (AI) chips everyone is so keen on. The order came from a leading customer, and will be employed in their next generation of application specific integrated circuits (ASICs). A dashedly clever bit of engineering, if I may say so.

Not to be outdone, Aehr followed this up on February 26th with news of a $14 million order for its FOX systems, WaferPak contractors, and Automated WaferPak Auto Aligners – a mouthful, certainly, but apparently essential for semiconductors used in AI data centers. One can only assume these contraptions are the bees’ knees, given the size of the order.

These announcements suggest that demand for Aehr’s AI-related products is picking up steam, supporting the rather optimistic view that the company might actually meet – or even exceed – its reinstated guidance for the 2026 fiscal year. After a brief period of pausing forecasts due to those pesky tariffs, Aehr now expects sales to come in between $25 million and $30 million this fiscal year, which concludes on May 30th. A modest sum, perhaps, but a sum nonetheless.

Management also hints that customer forecasts suggest bookings between $60 million and $80 million in the latter half of the fiscal year. With these new orders rolling in, the company’s outlook has brightened considerably. One must, however, remain cautiously optimistic. After all, one swallow does not make a summer.

Marching Onward

The good times continued into March, with Aehr announcing on the 3rd that it had received a new order from its top photonics customer for wafer-level test and burn-in solutions for optical architecture used in AI processors. A bit of a tongue-twister, that. Adding to the cheer, new jobs data from ADP showed the U.S. private sector adding 68,000 jobs in February – exceeding expectations. A pleasant surprise, wouldn’t you agree?

As of this writing, Aehr is up 8.2% this month and is valued at approximately 26 times this year’s expected sales. A rather lofty valuation, to be sure, especially considering the company’s somewhat uneven performance history. One can’t help but feel a touch of skepticism. However, it appears the company’s growth is poised to accelerate, driven by this AI-fueled demand. Whether this acceleration will be sustained remains to be seen, of course. One hopes for the best, but prepares for the possibility of a bit of a wobble along the way. After all, the stock market is a fickle beast, and prone to sudden, unexpected movements. It’s all a bit of a lark, really.

2026-03-06 15:42

A Surge of Contracts, By Jove!

Marching Onward

Read More